× About the Journal Scope of the Journal Contact Editor-in-Chief Editorial Board Current Issue Archives Abstracting And Indexing Submit Article Advertise Join As Reviewer Publishing Ethics


JAPER is indexed in SCOPUS

Orlistat - an anti-obesity drug - An overview


Ankita Taltia , Anitha Roy

Abstract

Obesity is the fifth leading risk for international deaths. At least 2.8 million adults die per annum as a result of overweight. The current recommendations for the treatment of obesity are embraced inflated physical activity and reduced calories intake. When the activity approach is not appropriate, a medical specialty treatment is usually recommended. Most anti-obesity drugs act on central nervous system to suppress appetite and reduce food intake. In past years, although varied medicines have been admitted for obesity treatmnet; due to the adverse effects, they have been withdrawn from further use. In fact, sibutramine licenses are withdrawn owing to an inflated risk of medical disorders and nonfatal infarct or stroke. Orlistat is presently the sole accessible selection for the treatment of obesity owing to its safety and positive effects. A gastric and pancreatic lipase inhibitor, otlistat, through reducing dietary fat absorption by approximately 30%, has been used for about 10 years. It also has a positive effect on the comorbidities of obesity and has a significant effect in reducing the risk factors of cardiovascular disease and diabetes mellitus. This article focuses on the efficacy, safety, and significance of orlistat.



DOWNLOAD


Contact SPER Publications


SPER Publications and Solutions Pvt. Ltd.

HD - 236,
Near The Shri Ram Millenium School,
Sector 135,
Noida-Greater Noida Expressway,
Noida-201301 [Delhi-NCR] India